<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883168</url>
  </required_header>
  <id_info>
    <org_study_id>MP4006</org_study_id>
    <nct_id>NCT00883168</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies</brief_title>
  <official_title>Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of two allergy medications
      (formulated azelastine/fluticasone product)is more effective than placebo or either component
      medication alone (azelastine or fluticasone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, randomized, double-blind, placebo-controlled, parallel-group study
      in subjects with moderate-to-severe seasonal allergic rhinitis (SAR). The study will begin
      with a 7-day, single-blind, placebo lead-in period (Day -7 to Day 1). Subjects will be
      instructed to take placebo lead-in medication twice daily (1 spray per nostril),
      approximately every 12 hours. On Day 1, subjects who satisfy the symptom severity
      requirements and continue to meet all of the study inclusion/exclusion criteria will be
      randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02,
      azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.

      Efficacy will be assessed by the change from baseline in the subject-reported 12-hour
      reflective Total Nasal Symptom Score (TNSS). On Days 1 through 14, subjects will rate the
      instantaneous and reflective TNSS symptoms of sneezing, nasal congestion, runny nose, and
      nasal itching; the instantaneous and reflective total ocular symptom score (TOSS) symptoms of
      itchy eyes, watery eyes and eye redness; the symptom of postnasal drip will be reflectively,
      twice daily (AM and PM) in a diary prior to the dose of study medication. Symptoms will be
      scored on a 0 to 3 scale (0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 =
      severe symptoms), such that the maximum daily symptom severity score will be 24 for the TNSS
      and 18 for the TOSS. Additional secondary efficacy variables will include reflective
      individual nasal and ocular symptom scores, as well as change from Baseline to Day 14 in the
      Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

      Subjects â‰¥ 18 years of age will complete the RQLQ on Day 1 (prior to dosing) and Day 14.
      Subjects will return to the clinic on Day 7 for an interim evaluation. After completing the
      2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at
      time of early termination) for an end-of-study evaluation. Safety and tolerability
      assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject-reported
      adverse events (AEs), nasal examinations, and vital signs assessments
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1791</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine Hcl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine Hcl /fluticasone propionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastineHcl</intervention_name>
    <description>azelastine hydrochloride 548 mg</description>
    <arm_group_label>azelastine Hcl</arm_group_label>
    <other_name>astelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>fluticasone propionate 200 mcg</description>
    <arm_group_label>fluticasone propionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine Hcl/fluticasone propionate</intervention_name>
    <description>azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg</description>
    <arm_group_label>azelastine Hcl /fluticasone propionate</arm_group_label>
    <other_name>MP29-02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/female subjects 12 years of age and older

          2. Provide written informed consent/pediatric assent.

          3. Subjects must have moderate-to-severe rhinitis, with one or more of the following
             present:

               1. Sleep disturbance

               2. Impairment of daily activities, leisure and/or sport

               3. Impairment of school or work

               4. Troublesome symptoms

          4. Screening Visit: Have a 12-hour reflective TNSS of at least 8 out of a possible 12 and
             a congestion score of 2 or 3 on Visit 1

          5. Randomization Visit: For the 3 days prior to Randomization and on the morning of
             Randomization, the sum of the 7 consecutive reflective AM and PM TNSS assessments
             shall be equal to or greater than 56, with a nasal congestion score equal to or
             greater than 14

          6. Randomization Visit: instantaneous TNSS score of at least 8 and a congestion score of
             at least 2 just prior to beginning the onset of action assessment

          7. Have taken at least 10 doses of the lead-in medication

          8. Willing and able to comply with the study requirements

          9. At least a 2-year history of SAR during the current allergy season

         10. The presence of IgE-mediated hypersensitivity to a prevailing, individual, seasonal
             pollen, confirmed by a positive response to skin prick within the last year.

         11. General good health and free of any disease or concomitant treatment that could
             interfere with the interpretation of the study results.

         12. Subjects receiving immunotherapy injections (antigen desensitization) must be on a
             stable maintenance regimen for at least 30 days before the first study visit

         13. Subjects currently receiving sublingual immunotherapy are excluded. A 6-month washout
             period is required following the last dose of sublingual immunotherapy.

        Exclusion Criteria:

          1. On Focused Nasal Examination, the presence of any superficial and moderate nasal
             mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1b - 4)
             at either the screening visit or randomization visit will disqualify the subject from
             the study.

          2. Other nasal disease(s) likely to affect deposition of intranasal medication.

          3. Nasal surgery or sinus surgery within the previous year.

          4. Chronic sinusitis - more than 3 episodes per year

          5. Planned travel outside of the pollen area during the study period

          6. The use of any investigational drug within 30 days prior to Visit 1. No
             investigational products are permitted for use during the conduct of this study

          7. Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or
             fluticasone propionate

          8. Women who are pregnant or nursing

          9. Women of childbearing potential who are not abstinent or not practicing a medically
             acceptable method of contraception* see section 6.1.1

         10. Respiratory Tract Infections within 14 days prior to Visit 1

         11. Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Visit 1

         12. Asthma (with the exception of intermittent asthma).

         13. Significant pulmonary disease including COPD

         14. Clinically significant arrhythmia or symptomatic cardiac conditions

         15. A known history of alcohol or drug abuse within the last 2 years

         16. Existence of any surgical or medical condition or physical or laboratory findings,
             might significantly alter the absorption, distribution, metabolism, or excretion of
             study drug; that might significantly affect the subject's ability to complete this
             trial; or their safety in this trial.

         17. Patients with a history of glaucoma

         18. Clinically relevant abnormal physical findings within 1 week of randomization may
             preclude compliance with the study procedures

         19. Employees of the research center or private practice and their family members

         20. no more than 50% of their subjects have participated in protocol MP4001, MP4002 or
             MP4004
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy, Asthma and Immunology Associates</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AABI Associates Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Care Center of So. Cal</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Research Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Medical Group Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Medical Group and Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bensch Research Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Storms Clinical Research Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze and Itch Associates</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy and Asthma</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy and Asthma Reserach</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Reseacrh Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Asthma and Allergy Center</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Asthma, Sinus and Allergy Centers</name>
      <address>
        <city>Warren</city>
        <state>New Jersey</state>
        <zip>07059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma and Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Consultants of NJ/PA</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <zip>19426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Clinical Immunology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy, Asthma and Urticaria of Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennesse Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research &amp; Consulting Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Sky Medical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Research Institute</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma, Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <results_first_submitted>May 21, 2012</results_first_submitted>
  <results_first_submitted_qc>August 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2012</results_first_posted>
  <disposition_first_submitted>June 23, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 18, 2011</disposition_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MP29-02</title>
          <description>azelastine HCl 548mcg / fluticasone propionate 200mcg</description>
        </group>
        <group group_id="P2">
          <title>Azelastine Hcl</title>
          <description>azelastine HCl nasal spray</description>
        </group>
        <group group_id="P3">
          <title>Fluticasone Propionate</title>
          <description>fluticasone propionate nasal spray</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>placebo nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="445"/>
                <participants group_id="P3" count="450"/>
                <participants group_id="P4" count="448"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="434"/>
                <participants group_id="P2" count="430"/>
                <participants group_id="P3" count="431"/>
                <participants group_id="P4" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP29-02</title>
          <description>azelastine HCl 548mcg / fluticasone propionate 200mcg</description>
        </group>
        <group group_id="B2">
          <title>Azelastine Hcl</title>
          <description>azelastine HCl nasal spray</description>
        </group>
        <group group_id="B3">
          <title>Fluticasone Propionate</title>
          <description>fluticasone propionate nasal spray</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>placebo nasal spray</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="448"/>
            <count group_id="B2" value="445"/>
            <count group_id="B3" value="450"/>
            <count group_id="B4" value="448"/>
            <count group_id="B5" value="1791"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                    <measurement group_id="B2" value="390"/>
                    <measurement group_id="B3" value="390"/>
                    <measurement group_id="B4" value="387"/>
                    <measurement group_id="B5" value="1549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="14.5"/>
                    <measurement group_id="B2" value="36.4" spread="14.8"/>
                    <measurement group_id="B3" value="34.2" spread="14.5"/>
                    <measurement group_id="B4" value="34.7" spread="14.1"/>
                    <measurement group_id="B5" value="35.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="280"/>
                    <measurement group_id="B4" value="269"/>
                    <measurement group_id="B5" value="1097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="445"/>
                    <measurement group_id="B3" value="450"/>
                    <measurement group_id="B4" value="448"/>
                    <measurement group_id="B5" value="1791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</title>
        <description>change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>Intent to Treat (ITT) population includes all subjects who had at least one post baseline dose efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>azelastine HCl 548mcg / fluticasone propionate 200mcg</description>
          </group>
          <group group_id="O2">
            <title>Azelastine Hcl</title>
            <description>azelastine HCl nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate</title>
            <description>fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)</title>
          <description>change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.</description>
          <population>Intent to Treat (ITT) population includes all subjects who had at least one post baseline dose efficacy evaluation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="445"/>
                <count group_id="O3" value="450"/>
                <count group_id="O4" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.2"/>
                    <measurement group_id="O2" value="-4.8" spread="4.8"/>
                    <measurement group_id="O3" value="-4.9" spread="4.7"/>
                    <measurement group_id="O4" value="-3.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
        <description>change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>Intent to Treat (ITT) population includes all subjects who received at least one post baseline efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>azelastine HCl 548mcg / fluticasone propionate 200mcg</description>
          </group>
          <group group_id="O2">
            <title>Azelastine Hcl</title>
            <description>azelastine HCl nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate</title>
            <description>fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
          <description>change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.</description>
          <population>Intent to Treat (ITT) population includes all subjects who received at least one post baseline efficacy evaluation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="443"/>
                <count group_id="O3" value="450"/>
                <count group_id="O4" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.3"/>
                    <measurement group_id="O2" value="-4.3" spread="4.9"/>
                    <measurement group_id="O3" value="-4.7" spread="4.9"/>
                    <measurement group_id="O4" value="-3.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</title>
        <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>Intent to treat (ITT)population includes all subjects(18 years or older) who had at least one post baseline efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>azelastine HCl 548mcg / fluticasone propionate 200mcg</description>
          </group>
          <group group_id="O2">
            <title>Azelastine Hcl</title>
            <description>azelastine HCl nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate</title>
            <description>fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</title>
          <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.</description>
          <population>Intent to treat (ITT)population includes all subjects(18 years or older) who had at least one post baseline efficacy evaluation</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="394"/>
                <count group_id="O3" value="384"/>
                <count group_id="O4" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.3"/>
                    <measurement group_id="O2" value="-1.4" spread="1.3"/>
                    <measurement group_id="O3" value="-1.6" spread="1.2"/>
                    <measurement group_id="O4" value="-1.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MP29-02</title>
          <description>azelastine HCl 548mcg / fluticasone propionate 200mcg</description>
        </group>
        <group group_id="E2">
          <title>Azelastine Hcl</title>
          <description>azelastine HCl nasal spray</description>
        </group>
        <group group_id="E3">
          <title>Fluticasone Propionate</title>
          <description>fluticasone propionate nasal spray</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>medra 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">pyogenic arthritis right elbow</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="448"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>lacerated right hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="448"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="449"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="450"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysgusia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="448"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="449"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>oropharyngial pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="448"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="450"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="448"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="450"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="448"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="449"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="450"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="448"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="448"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="450"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="448"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="449"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="450"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>mucosal erosion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="448"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="450"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.
Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Ginsberg,D.O.</name_or_title>
      <organization>Meda Pharmaceuticals, Inc.</organization>
      <phone>732 564-2364</phone>
      <email>david.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

